No Effective Oral Medications for Sporadic Acoustic Neuroma
There are no oral medications proven effective for treating sporadic acoustic neuromas (vestibular schwannomas), and pharmacotherapy plays no role in their management except for bevacizumab in neurofibromatosis type 2 (NF2) patients. 1
Evidence-Based Treatment Landscape
The 2020 EANO guideline explicitly states that "except for bevacizumab in neurofibromatosis type 2, there is no role for pharmacotherapy" in vestibular schwannoma management 1. This represents the most authoritative and recent consensus on medical therapy for these tumors.
Standard Treatment Options for Sporadic VS
For sporadic acoustic neuromas, your treatment algorithm should be:
- Small, asymptomatic tumors: Observation with serial MRI imaging
- Small tumors requiring intervention: Stereotactic radiosurgery (SRS) preferred for hearing/facial nerve preservation
- Large tumors with mass effect: Surgical decompression as primary treatment
- Post-surgical residual: Consider SRS or continued observation 1
Investigated Oral Agents (Limited Evidence)
While several oral medications have been studied, none have demonstrated sufficient efficacy to warrant clinical use:
Aspirin and NSAIDs
Level 3 evidence suggests aspirin may prevent tumor growth during observation 2, but this recommendation is weak. A 2026 meta-analysis found no significant association between NSAID use and tumor growth (pooled OR: 0.77; 95% CI: 0.48-1.23) 3. A 2019 volumetric analysis similarly showed neither 81mg nor 325mg aspirin reduced growth risk 4.
Clinical Bottom Line: Despite initial promise, the preponderance of evidence does not support aspirin use for preventing VS growth.
Metformin
A 2026 meta-analysis showed metformin users had lower odds of tumor growth (pooled OR: 0.46; 95% CI: 0.30-0.72), but this is based entirely on retrospective level 3 evidence 3. No prospective trials exist, and routine use cannot be recommended.
Perioperative Nimodipine
Level 3 evidence supports perioperative nimodipine (with or without hydroxyethyl starch) to improve postoperative facial nerve outcomes 2. This is the only oral medication with any guideline-level recommendation, but it's for surgical adjunct use, not tumor treatment.
NF2-Associated VS: The Exception
For NF2 patients specifically:
- Bevacizumab (IV, not oral): Level 3 recommendation for radiographic tumor reduction and hearing preservation 2
- Lapatinib (oral TKI): May be considered for tumor size reduction and hearing improvement in NF2 (Level 3) 2
- Erlotinib and everolimus: Not recommended (ineffective) 2
Critical Caveats
Important: The question asks about oral drugs, but bevacizumab—the only medication with any established role—is administered intravenously, not orally. Even in NF2 patients, its benefits are temporary, with tumor regrowth occurring after discontinuation 5, 6.
For sporadic VS patients asking about medical therapy: Counsel them that observation, surgery, and radiosurgery remain the only evidence-based options. No pill can shrink or control their tumor. Focus counseling on the natural history: during observation, only 47% maintain serviceable hearing at 10 years 7, which helps frame treatment timing decisions.